Your browser doesn't support javascript.
loading
Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes.
Miguel-Escalada, Irene; Bonàs-Guarch, Silvia; Cebola, Inês; Ponsa-Cobas, Joan; Mendieta-Esteban, Julen; Atla, Goutham; Javierre, Biola M; Rolando, Delphine M Y; Farabella, Irene; Morgan, Claire C; García-Hurtado, Javier; Beucher, Anthony; Morán, Ignasi; Pasquali, Lorenzo; Ramos-Rodríguez, Mireia; Appel, Emil V R; Linneberg, Allan; Gjesing, Anette P; Witte, Daniel R; Pedersen, Oluf; Grarup, Niels; Ravassard, Philippe; Torrents, David; Mercader, Josep M; Piemonti, Lorenzo; Berney, Thierry; de Koning, Eelco J P; Kerr-Conte, Julie; Pattou, François; Fedko, Iryna O; Groop, Leif; Prokopenko, Inga; Hansen, Torben; Marti-Renom, Marc A; Fraser, Peter; Ferrer, Jorge.
Afiliação
  • Miguel-Escalada I; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Bonàs-Guarch S; Regulatory Genomics and Diabetes, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Cebola I; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
  • Ponsa-Cobas J; Genomic Programming of Beta Cells Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Mendieta-Esteban J; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Atla G; Regulatory Genomics and Diabetes, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Javierre BM; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
  • Rolando DMY; Genomic Programming of Beta Cells Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Farabella I; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Morgan CC; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • García-Hurtado J; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Beucher A; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Morán I; Regulatory Genomics and Diabetes, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Pasquali L; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
  • Ramos-Rodríguez M; Genomic Programming of Beta Cells Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Appel EVR; Nuclear Dynamics Programme, The Babraham Institute, Cambridge, UK.
  • Linneberg A; Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Barcelona, Spain.
  • Gjesing AP; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Witte DR; CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Pedersen O; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Grarup N; Regulatory Genomics and Diabetes, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Ravassard P; Regulatory Genomics and Diabetes, Centre for Genomic Regulation, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Torrents D; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
  • Mercader JM; Genomic Programming of Beta Cells Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Piemonti L; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • Berney T; Section of Epigenomics and Disease, Department of Medicine, and National Institute for Health Research Imperial Biomedical Research Centre, Imperial College London, London, UK.
  • de Koning EJP; Barcelona Supercomputing Center, Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona, Spain.
  • Kerr-Conte J; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain.
  • Pattou F; Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Barcelona, Spain.
  • Fedko IO; Endocrine Regulatory Genomics Laboratory, Germans Trias i Pujol University Hospital and Research Institute, Barcelona, Spain.
  • Groop L; Endocrine Regulatory Genomics Laboratory, Germans Trias i Pujol University Hospital and Research Institute, Barcelona, Spain.
  • Prokopenko I; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hansen T; Center for Clinical Research and Disease Prevention, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Marti-Renom MA; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Fraser P; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Ferrer J; Department of Public Health, Aarhus University, Aarhus, Denmark.
Nat Genet ; 51(7): 1137-1148, 2019 07.
Article em En | MEDLINE | ID: mdl-31253982
ABSTRACT
Genetic studies promise to provide insight into the molecular mechanisms underlying type 2 diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer clusters or super-enhancers. So far, such domains have been defined through clustering of enhancers in linear genome maps rather than in three-dimensional (3D) space. Furthermore, their target genes are often unknown. We have created promoter capture Hi-C maps in human pancreatic islets. This linked diabetes-associated enhancers to their target genes, often located hundreds of kilobases away. It also revealed >1,300 groups of islet enhancers, super-enhancers and active promoters that form 3D hubs, some of which show coordinated glucose-dependent activity. We demonstrate that genetic variation in hubs impacts insulin secretion heritability, and show that hub annotations can be used for polygenic scores that predict T2D risk driven by islet regulatory variants. Human islet 3D chromatin architecture, therefore, provides a framework for interpretation of T2D genome-wide association study (GWAS) signals.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Regulação da Expressão Gênica / Ilhotas Pancreáticas / Elementos Facilitadores Genéticos / Diabetes Mellitus Tipo 2 / Redes Reguladoras de Genes / Secreção de Insulina Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Regulação da Expressão Gênica / Ilhotas Pancreáticas / Elementos Facilitadores Genéticos / Diabetes Mellitus Tipo 2 / Redes Reguladoras de Genes / Secreção de Insulina Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article